TECENTRIQ®
atezolizumab INJECTION FOR INTRAVENOUS USE 1200 mg

On behalf of Genentech, you are invited to attend an expert-led educational presentation

Introducing TECENTRIQ®: For Previously Treated Metastatic Non-Small Cell Lung Cancer

Thursday, March 30, 2017
Arrival Time: 6:00 PM
Presentation Time: 6:30 PM

Le Papillon
410 Saratoga Avenue
San Jose, CA, 95129

FEATURED FACULTY
Robert Weber, MD
Weber and Yamamoto
San Francisco, CA

Please RSVP by Thursday, March 23, 2017 to:
Katrina Custodio at (650) 273-3180 &
Custodio.Katrina@Gene.Com

or at http://www.medforcereg.net/SGEN7710

PROGRAM OBJECTIVES:

- Provide an overview of non-small cell lung cancer (NSCLC)
- Describe TECENTRIQ and its mechanism of action
- Present pivotal data from 2 randomized clinical trials
- Identify appropriate patient candidates with NSCLC for TECENTRIQ
- Review Important Safety Information
  - Describe warnings and precautions and additional information
- Provide PI recommendations for managing immune-related adverse events

INDICATION AND USAGE

TECENTRIQ is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving TECENTRIQ.

Minnesota, Vermont, the Department of Defense, and the Department of Veterans Affairs have restrictions on receiving meals at company-sponsored events. You are accountable for understanding such restrictions and complying with them. If you are licensed in or affiliated with any of these states or federal agencies, Genentech policies may restrict your participation in this event. Your local Genentech representative can help you determine if our policies permit your attendance. When you RSVP, please indicate whether you will accept or opt out of accepting a meal at the program. If you choose to opt out, you may either pay for the meal on your own or not consume anything at the program.

For all attendees who opt in to accept a meal paid for by Genentech at this event, Genentech will report the attendee's name and value of the meal, as required by federal and state disclosure laws (for more information on the federal law please visit http://sunshine.gene.com). The meal cost may vary by event location and be up to $125 per person (exceptions may apply).

Please see accompanying full Prescribing Information and reverse for Important Safety Information.

Genentech
A Member of the Roche Group

IMPORTANT SAFETY INFORMATION

Serious Adverse Reactions

Please refer to the full Prescribing Information for important dose management information specific to adverse reactions.

- **Immune-related pneumonitis.** Immune-mediated pneumonitis or interstitial lung disease, including fatal cases, occurred. Permanently discontinue TECENTRIQ for Grade 3 or 4 pneumonitis
- **Immune-related hepatitis.** Immune-mediated hepatitis, including a fatal case in urothelial carcinoma (UC), and liver test abnormalities occurred. Permanently discontinue TECENTRIQ for Grade 3 or 4 immune-mediated hepatitis
- **Immune-related colitis.** Immune-mediated colitis or diarrhea, including a fatal case of diarrhea-associated renal failure in UC, occurred. Permanently discontinue TECENTRIQ for Grade 4 diarrhea or colitis
- **Immune-related endocrinopathies.** Immune-related thyroid disorders, adrenal insufficiency, hypophysitis, and type 1 diabetes mellitus, including diabetic ketoacidosis, have occurred. Permanently discontinue TECENTRIQ for Grade 4 hypophysitis
- **Other immune-related adverse reactions.** Meningoencephalitis, myasthenic syndrome/myasthenia gravis, Guillain-Barré syndrome, ocular inflammatory toxicity, and pancreatitis, including increases in serum amylase and lipase levels, have occurred. Permanently discontinue TECENTRIQ for any grade of meningitis or encephalitis, or any grade of myasthenic syndrome/myasthenia gravis or Guillain-Barré syndrome. Permanently discontinue TECENTRIQ for Grade 4 or any grade of recurrent pancreatitis
- **Infection.** Severe infections, including fatal cases, occurred. Sepsis, herpes encephalitis, and mycobacterial infection leading to retroperitoneal hemorrhage have been observed
- **Infusion-related reactions.** Severe infusion reactions have occurred. Permanently discontinue TECENTRIQ in patients with Grade 3 or 4 infusion reactions
- **Embryo-fetal toxicity.** TECENTRIQ can cause fetal harm in pregnant women. Advise patients of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TECENTRIQ and for at least 5 months after the last dose
- Advise female patients not to breastfeed while taking TECENTRIQ and for at least 5 months after the last dose

Most Common Adverse Reactions

The most common adverse reactions (rate ≥20%) included fatigue (46%), decreased appetite (35%), dyspnea (32%), cough (30%), nausea (22%), musculoskeletal pain (22%), and constipation (20%).

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see accompanying full Prescribing Information for additional Important Safety Information.

This event is sponsored by Genentech, Inc. No continuing education credits.

Genentech
A Member of the Roche Group

TECENTRIQ®
atezolizumab INJECTION FOR INTRAVENOUS USE 1200 mg